POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.

New Reporting Requirement for Psychedelic Drugs in VA Healthcare

Original title: HR 7347: Bill to Study Psychedelic Drugs for Veterans

Record date · September 6, 2024

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

This bill requires the Secretary of Veterans Affairs to submit a formal report to Congress explaining whether or not the Department will include newly FDA-approved or licensed psychedelic drugs in its official list of covered medications.

Why it matters

This legislation establishes a mandatory 180-day timeline for the VA to justify its coverage decisions regarding emerging psychedelic treatments, directly impacting the availability of these therapies for veterans enrolled in the VA healthcare system.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Veterans enrolled in VA healthcare

The bill dictates the timeline and transparency of decisions regarding the availability of new psychedelic treatments within their healthcare system.

Directly affected

Secretary of Veterans Affairs

The Secretary is mandated to perform new reporting duties and provide justifications for formulary decisions.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Does this bill force the VA to cover psychedelic drugs?
No. The bill only requires the Secretary of Veterans Affairs to report their decision and provide a justification for whether or not they will include a newly approved psychedelic drug in the VA .
How quickly must the VA report on a new drug?
The Secretary must submit the report to the Committees on Veterans' Affairs of the Senate and House of Representatives not later than 180 days after the drug is approved or licensed.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently filed. The next step in the legislative lifecycle is Committee.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Formalizing Psychedelic Review

The bill signals a move toward integrating specific, emerging drug classes into the VA's formal administrative review and reporting framework.

Connected Entities

Secretary of Veterans Affairs, title 38, United States Code, certain psychedelic drugs and 2 more
OrganizationSecretary of Veterans Affairs“The executive branch official responsible for overseeing VA operations.”Map →
bill numbertitle 38, United States Code“The specific section of the U.S. Code being amended.”Map →
othercertain psychedelic drugs“Specifically, the bill references research into drugs like psilocybin and MDMA.”Map →
OrganizationDepartment of Veterans Affairs“The federal agency responsible for providing benefits and services to veterans.”Map →
otherUnited States Code“The official codified collection of federal laws.”Map →

Sources

Open source document

www.congress.gov

Analysis Score

0–100
  • Significance65
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz35
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record